397 related articles for article (PubMed ID: 33974093)
41. An in vitro evaluation of antitumor activity of sirolimus-encapsulated liposomes in breast cancer cells.
Nandi U; Onyesom I; Douroumis D
J Pharm Pharmacol; 2021 Mar; 73(3):300-309. PubMed ID: 33793879
[TBL] [Abstract][Full Text] [Related]
42. Evaluation the Anti-Cancer Effect of PEGylated Nano-Niosomal Gingerol, on Breast Cancer Cell lines (T47D), In-Vitro.
Behroozeh A; Mazloumi Tabrizi M; Kazemi SM; Choupani E; Kabiri N; Ilbeigi D; Heidari Nasab A; Akbarzadeh Khiyavi A; Seif Kurdi A
Asian Pac J Cancer Prev; 2018 Mar; 19(3):645-648. PubMed ID: 29580033
[TBL] [Abstract][Full Text] [Related]
43. Emerging nanotherapeutic strategies in breast cancer.
Blanco E; Ferrari M
Breast; 2014 Feb; 23(1):10-8. PubMed ID: 24215984
[TBL] [Abstract][Full Text] [Related]
44. Recent advances and clinical translation of liposomal delivery systems in cancer therapy.
Chen J; Hu S; Sun M; Shi J; Zhang H; Yu H; Yang Z
Eur J Pharm Sci; 2024 Feb; 193():106688. PubMed ID: 38171420
[TBL] [Abstract][Full Text] [Related]
45. Liposomes for Pulmonary Drug Delivery: The Role of Formulation and Inhalation Device Design.
Elhissi A
Curr Pharm Des; 2017; 23(3):362-372. PubMed ID: 27848886
[TBL] [Abstract][Full Text] [Related]
46. Liposome-based diagnostic and therapeutic applications for pancreatic cancer.
Raza F; Evans L; Motallebi M; Zafar H; Pereira-Silva M; Saleem K; Peixoto D; Rahdar A; Sharifi E; Veiga F; Hoskins C; Paiva-Santos AC
Acta Biomater; 2023 Feb; 157():1-23. PubMed ID: 36521673
[TBL] [Abstract][Full Text] [Related]
47. Enhancement of the uptake and cytotoxic activity of doxorubicin in cancer cells by novel cRGD-semipeptide-anchoring liposomes.
Battistini L; Burreddu P; Sartori A; Arosio D; Manzoni L; Paduano L; D'Errico G; Sala R; Reia L; Bonomini S; Rassu G; Zanardi F
Mol Pharm; 2014 Jul; 11(7):2280-93. PubMed ID: 24819754
[TBL] [Abstract][Full Text] [Related]
48. PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure.
Mo L; Song JG; Lee H; Zhao M; Kim HY; Lee YJ; Ko HW; Han HK
Nanomedicine; 2018 Feb; 14(2):557-567. PubMed ID: 29248675
[TBL] [Abstract][Full Text] [Related]
49. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.
Malam Y; Loizidou M; Seifalian AM
Trends Pharmacol Sci; 2009 Nov; 30(11):592-9. PubMed ID: 19837467
[TBL] [Abstract][Full Text] [Related]
50. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
Cheema SK; Gobin AS; Rhea R; Lopez-Berestein G; Newman RA; Mathur AB
Int J Pharm; 2007 Aug; 341(1-2):221-9. PubMed ID: 17499461
[TBL] [Abstract][Full Text] [Related]
51. Topical Triamcinolone Acetonide-Loaded Liposomes as Primary Therapy for Macular Edema Secondary to Branch Retinal Vein Occlusion: A Pilot Study.
Navarro-Partida J; Altamirano-Vallejo JC; Lopez-Naranjo EJ; Gonzalez-De la Rosa A; Manzano-RamÃrez A; Apatiga-Castro LM; Armendáriz-Borunda J; Santos A
J Ocul Pharmacol Ther; 2020; 36(6):393-403. PubMed ID: 32564664
[No Abstract] [Full Text] [Related]
52. Nanomedicine in treatment of breast cancer - A challenge to conventional therapy.
Afzal M; Ameeduzzafar ; Alharbi KS; Alruwaili NK; Al-Abassi FA; Al-Malki AAL; Kazmi I; Kumar V; Kamal MA; Nadeem MS; Aslam M; Anwar F
Semin Cancer Biol; 2021 Feb; 69():279-292. PubMed ID: 31870940
[TBL] [Abstract][Full Text] [Related]
53. Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery.
Amreddy N; Babu A; Muralidharan R; Panneerselvam J; Srivastava A; Ahmed R; Mehta M; Munshi A; Ramesh R
Adv Cancer Res; 2018; 137():115-170. PubMed ID: 29405974
[TBL] [Abstract][Full Text] [Related]
54. Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment.
La-Beck NM; Liu X; Shmeeda H; Shudde C; Gabizon AA
Semin Cancer Biol; 2021 Jan; 68():175-185. PubMed ID: 31874280
[TBL] [Abstract][Full Text] [Related]
55. A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice.
Zhang D; Baldwin P; Leal AS; Carapellucci S; Sridhar S; Liby KT
Theranostics; 2019; 9(21):6224-6238. PubMed ID: 31534547
[TBL] [Abstract][Full Text] [Related]
56. Temperature-sensitive liposomes for co-delivery of tamoxifen and imatinib for synergistic breast cancer treatment.
Jose A; Ninave KM; Karnam S; Venuganti VVK
J Liposome Res; 2019 Jun; 29(2):153-162. PubMed ID: 30022700
[TBL] [Abstract][Full Text] [Related]
57. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy.
Chang HI; Yeh MK
Int J Nanomedicine; 2012; 7():49-60. PubMed ID: 22275822
[TBL] [Abstract][Full Text] [Related]
58. Liposomal drug delivery systems--clinical applications.
Goyal P; Goyal K; Vijaya Kumar SG; Singh A; Katare OP; Mishra DN
Acta Pharm; 2005 Mar; 55(1):1-25. PubMed ID: 15907221
[TBL] [Abstract][Full Text] [Related]
59. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
60. From conventional to stealth liposomes: a new frontier in cancer chemotherapy.
Cattel L; Ceruti M; Dosio F
Tumori; 2003; 89(3):237-49. PubMed ID: 12908776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
